https://scholars.lib.ntu.edu.tw/handle/123456789/484091
標題: | Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size | 作者: | ZHONG-ZHE LIN Shau W.-Y. CHIUN HSU YU-YUN SHAO Yeh Y.-C. Kuo R.N.-C. CHIH-HUNG HSU CHIH-HSIN YANG ANN-LII CHENG Lai M.-S. |
公開日期: | 2013 | 卷: | 8 | 期: | 11 | 來源出版物: | PLoS ONE | 摘要: | Background: Randomized trials suggest that radiofrequency ablation (RFA) may be more effective than percutaneous ethanol injection (PEI) in the treatment of hepatocellular carcinoma (HCC). However, the survival advantage of RFA needs confirmation in daily practice. Methods: We conducted a population-based cohort study using the Taiwan Cancer Registry, National Health Insurance claim database and National Death Registry data from 2004 through 2009. Patients receiving PEI or RFA as first-line treatment for newly-diagnosed stage I-II HCC were enrolled. Results: A total of 658 patients receiving RFA and 378 patients receiving PEI treatment were included for final analysis. The overall survival (OS) rates of patients in the RFA and PEI groups at 5-year were 55% and 42%, respectively (p < 0.01). Compared to patients that received PEI, those that received RFA had lower risks of overall mortality and first-line treatment failure (FTF), with adjusted hazard ratios (HRs) [95% confidence interval (CI)] of 0.60 (0.50-0.73) for OS and 0.54 (0.46-0.64) for FTF. The favorable outcomes for the RFA group were consistently significant for patients with tumors > 2 cm as well as for those with tumors < 2 cm. Consistent results were also observed in other subgroup analyses defined by gender, age, tumor stage, and co-morbidity status. Conclusion: RFA provides better survival benefits than PEI for patients with unresectable stage I-II HCC, irrespective of tumors > 2 cm or ? 2 cm, in contemporary clinical practice. ? 2013 Lin et al. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84893182239&doi=10.1371%2fjournal.pone.0080276&partnerID=40&md5=bb3f0c3f9a27712092f167f487f91dc9 https://scholars.lib.ntu.edu.tw/handle/123456789/484091 |
ISSN: | 1932-6203 | DOI: | 10.1371/journal.pone.0080276 | SDG/關鍵字: | alcohol; alcohol; adult; age; article; cancer mortality; cancer registry; cancer staging; cohort analysis; comorbidity; female; human; intermethod comparison; liver cell carcinoma; major clinical study; male; middle aged; overall survival; population research; radiofrequency ablation; risk reduction; sex difference; Taiwan; treatment failure; treatment outcome; tumor volume; Carcinoma, Hepatocellular; catheter ablation; chemoembolization; intradermal drug administration; Liver Neoplasms; Administration, Cutaneous; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Cohort Studies; Ethanol; Female; Humans; Liver Neoplasms; Male; Middle Aged; Taiwan; Treatment Outcome |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。